Headquartered in Burlington, MA, Dyax is working to usurp its own Kalbitor, a subcutaneous treatment for HAE attacks approved in 2009. Since that treatment's debut, rivals Shire ($SHPG) and Salix, now part of Valeant Pharmaceuticals ($VRX), have launched HAE treatments of their own, and Dyax pulls in about $65 million a year from its sole marketed therapy.
Als Valeant een Ruconest-omzet zou maken van 65 miljoen per jaar, dan zou Pharming dus ca 20 M USD ontvangen, oftewel ca 4,5 M euro per kwartaal.